NHFG
VRTX icon

New Harbor Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

New Harbor Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300
Closed -$121K – 84
2024
Q4 		$121K Sell
300
-50
-14% -$23.2K 0.04% 64
2024
Q3 		$163K Buy
+350
New +$168K 0.04% 56

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

New Harbor Financial Group's VRTX Position: Q1 2025 in Review

New Harbor Financial Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 300 shares — an estimated $121K sold.

New Harbor Financial Group first reported a position in VRTX in Q3 2024 and held it in 2 quarters. The position peaked at $163K in Q3 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • New Harbor Financial Group reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • New Harbor Financial Group sold 300 Vertex Pharmaceuticals shares in Q1 2025, an estimated $121K.
  • New Harbor Financial Group first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • New Harbor Financial Group's Vertex Pharmaceuticals position peaked at $163K in Q3 2024.
  • 1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on New Harbor Financial Group's 13F filing for Q1 2025, filed 14 May 2025.